INTRODUCTION
Cardiovascular (CV) disease is the leading cause of mortality and morbidity in patients with type 2 diabetes mellitus (T2DM) Each 1% increase in HbA1c increases the risk of heart failure (HF) hospitalization or HF death by 8%.
The US FDA recommended in 2008 that CV safety should be assessed as a component of the clinical development program of new antihyperglycemic drugs Saxagliptin is an orally active DPP-4 inhibitor approved for glycemic control in adults with T2DM Cardiovascular safety of saxagliptin (and other DPP-4 inhibitors) is controversial with the recently reported SAVOR-TIMI 53 study suggesting that saxagliptin is associated with an increased risk of hospitalization due to heart failure To evaluate the association between saxagliptin and cardiovascular risk in patients with type 2 diabetes mellitus (T2DM)
OBJECTIVE
Literature searches were performed in PubMed, CENTRAL, and ClinicalTrials.gov databases from inception An initial search using the Terms "diabetes mellitus", "saxaglptin", "safety", and "cardiovascular" was followed by a search of related citations All randomised controlled trials (RCTs) that compared saxagliptin against placebo, or active antidiabetic drugs in adult patients (≥18 years) with T2DM, and reported cardiovascular outcomes were included.
In addition, references of the included studies were screened for additional studies Four authors independently screened titles, abstracts and subsequently the full texts of all the potentially relevant studies. The same four authors extracted data and assessed risk of bias using the modified Jadad scale
MATERIALS AND METHODS
The risk of cardiovascular mortality was comparable between saxagliptin 2.5mg and comparator (OR 0.80, 95% CI 0.25 to 2.54,2 trials, n=886) The risk of cardiovascular mortality was comparable between saxagliptin 5 mg and comparator (OR 1.25, 95% CI 0.44 to 3.55, 2 trials, n=890)
The risk of myocardial infarction (MI) was comparable between saxagliptin 2.5 mg and comparator [odds ratio (OR) 0.22, 95% confidence interval (CI) 0.04 to 1.31, 3 trials, n=1083]
The risk of MI was comparable between saxagliptin 5 mg and comparator (OR 0.61, 95% CI 0.19 to 1.96, 6 trials, n=2762 )
DISCUSSION
Presently available drugs for the pharmacotherapy of T2DM, apart from Insulin, include metformin, the insulin secretagogues (sulfonylureas and meglitinides), thiazolidinediones, α-glucosidase inhibitors, the amylin analogue pramlintide, GLP-1 agonists, and the dipeptidyl peptidase 4 inhibitors (DPP4is).
DPP-4 inhibitors inhibit the inactivation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide, resulting in increased glucose-dependent insulin secretion and suppression of glucagon secretion.
Saxagliptin is a useful drug for the treatment of type 2 diabetes, both as monotherapy and in combination with other antihyperglycemic drugs
The recently reported SAVOR-TIMI 53 trial demonstrated that saxagliptin did not increase or decrease the rate of ischemic events Subsequently, an analysis of pooled data from 20 clinical trials comprising over 9000 patients with T2DM confirmed that saxagliptin was not associated with an increased risk for ischemic events However, it was observed that the rate of hospitalization for heart failure was increased after treatment with saxagliptin This increase in heart failure hospitalization risk was seen irrespective of age category, being highest among patients with elevated levels of natriuretic peptides, previous heart failure, or chronic kidney disease 
CONCLUSION
Evidence suggests no increased risk of MI, cardiovascular mortality, CHF, or angina pectoris with saxagliptin 2.5 mg or 5 mg in T2DM patients However, limited evidence suggests that saxagliptin 5 mg is associated with increased risk of heart failure among T2DM patients 
G
The risk of congestive heart failure (CHF) was comparable between saxagliptin 2.5mg and comparator (OR 0.23,95% CI 0.03 to 2.09, 2 trials, n=749)
The risk of CHF was comparable between saxagliptin 5 mg and comparator (OR 0.95, 95% CI 0.21 to 4.22, 2 trials, n=741)
B E
The risk of angina pectoris was comparable between saxagliptin 2.5 mg and comparator (OR 0.33, 95% CI 0.05 to 2.08, 4 trials, n=1412) The risk of angina pectoris was comparable between saxagliptin 5 mg and comparator (OR 0.70, 95% CI 0.20 to 2.51, 6 trials, n=2010).
At week 24,the odds of heart failure with saxagliptin(5mg) was 1.8 times higher than comparator (OR 1.78,95% CI 1.27to2.50, 4 trials, n=17796).
A total of 19 trials involving 26778 patients were included, with a mean HbA1c of 8.2±0.8%, mean age 56±10.11 years, and mean BMI 30.2±4.9 kg/m2
A total of 14649 received saxagliptin once daily and 12129 received comparators.
Overall, the risk of bias of included trials was low
